SOBRERA PHARMA RECEIVES PATENT APPROVAL IN THE USA
The United States Patent and Trademark Office (USPTO) has granted a new patent US 11,318,143 further strengthening the Company’s Intellectual property position and coverage for the Company’s therapeutic drug candidate SO-001.
The decision to grant of the patent titled ‘Treatment of Alcohol Use Disorder’ covers the use of
varenicline in combination with bupropion for the use in treating Alcohol Use Disorders (AUD)
and/or treating alcohol risk consumption.